eslicarbazepine acetate has been researched along with Cranial Nerve V Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Micov, A; Pecikoza, U; Stepanović-Petrović, R; Tomić, M; Vuković, M | 1 |
| Micov, AM; Pecikoza, UB; Stepanović-Petrović, RM; Tomić, MA | 1 |
2 other study(ies) available for eslicarbazepine acetate and Cranial Nerve V Diseases
| Article | Year |
|---|---|
Eslicarbazepine acetate interacts in a beneficial manner with standard and alternative analgesics to reduce trigeminal nociception.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Dibenzazepines; Male; Metoclopramide; Mice; Nociception; Pain; Pain Measurement; Rats, Sprague-Dawley; Stress, Psychological; Trigeminal Nerve Diseases | 2020 |
The Efficacy of Eslicarbazepine Acetate in Models of Trigeminal, Neuropathic, and Visceral Pain: The Involvement of 5-HT1B/1D Serotonergic and CB1/CB2 Cannabinoid Receptors.
Topics: Animals; Diabetic Neuropathies; Dibenzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred C57BL; Pain Measurement; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Treatment Outcome; Trigeminal Nerve Diseases; Visceral Pain | 2015 |